Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Amy Wesa"'
Autor:
Garima Kaushik, Amy Wesa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7434e03bf7794ba68c33f056e54b79ab
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/2ce89dc55e9d4e53b17e6ebbaab6a7f0
Autor:
Brooke M. Helfer, Anthony Balducci, Zhina Sadeghi, Charles O'hanlon, Adonis Hijaz, Chris A. Flask, Amy Wesa
Publikováno v:
Cell Transplantation, Vol 22 (2013)
Hematopoietic stem cells (HSCs) have numerous therapeutic applications including immune reconstitution, enzyme replacement, regenerative medicine, and immunomodulation. The trafficking and persistence of these cells after administration is a fundamen
Externí odkaz:
https://doaj.org/article/426876e5374d4347be9937df08f30b30
Autor:
Garima, Kaushik, Shivaprasad, Venkatesha, Bhavna, Verma, Bandana, Vishwakarma, Ai-Hong, Zhang, Amy, Wesa
Publikováno v:
The Cancer Journal. 28:257-262
Adoptive cellular therapies are making major strides in the treatment of cancer, both for hematologic and solid tumors. These cellular products include chimeric antigen receptor T cells and T-cell receptor-modified T cells, tumor-infiltrating lymphoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65ffe821018afeadd2b12744f993f7c
https://doi.org/10.1097/ppo.0000000000000609
https://doi.org/10.1097/ppo.0000000000000609
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2efa1fb2eca5731e15fb0928e1e7b7
https://doi.org/10.1158/1535-7163.c.6543438.v1
https://doi.org/10.1158/1535-7163.c.6543438.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6636bc7fd14949c096b587e72af567
https://doi.org/10.1158/1535-7163.22522569.v1
https://doi.org/10.1158/1535-7163.22522569.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Supplementary Data from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a65e018c5371d1a9a5d2dd985a27fdf8
https://doi.org/10.1158/1535-7163.22522572.v1
https://doi.org/10.1158/1535-7163.22522572.v1
Autor:
Hideho Okada, Walter J. Storkus, Paul R. Walker, Douglas M. Potter, Amy Wesa, Mitsugu Fujita, Jian Huang, Jill E. Dusak, Fumihiko Nishimura, Cecilia Vasquez, Xinmei Zhu, Kotaro Sasaki
Supplementary Figures 1-3 from Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128391570c317b1d5ac6eaa7510aa708
https://doi.org/10.1158/0008-5472.22365723.v1
https://doi.org/10.1158/0008-5472.22365723.v1
Autor:
Hideho Okada, Walter J. Storkus, Paul R. Walker, Douglas M. Potter, Amy Wesa, Mitsugu Fujita, Jian Huang, Jill E. Dusak, Fumihiko Nishimura, Cecilia Vasquez, Xinmei Zhu, Kotaro Sasaki
We have previously shown preferential tumor-homing and therapeutic efficacy of adoptively transferred type 1 CTL (Tc1) when compared with type 2 CTL (Tc2) in mice bearing intracranial ovalbumin-transfected melanoma (M05). Further characterizing the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c58c101d3dfdaf645f71cbc31254dcd
https://doi.org/10.1158/0008-5472.c.6494832
https://doi.org/10.1158/0008-5472.c.6494832
Autor:
Gilad Silberberg, Brandon Walling, Amy Wesa, Alessandra Audia, Ido Sloma, Yi Zeng, Guanghui Han, Jia Tang, Paige Pammer
Publikováno v:
Archives of Clinical and Biomedical Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65c7d071c313f261b767bafa1b5afd90
https://doi.org/10.26502/acbr.50170321
https://doi.org/10.26502/acbr.50170321